912 Shares in Stryker Co. (NYSE:SYK) Purchased by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. acquired a new stake in shares of Stryker Co. (NYSE:SYK - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 912 shares of the medical technology company's stock, valued at approximately $328,000.

A number of other large investors have also bought and sold shares of SYK. Annis Gardner Whiting Capital Advisors LLC raised its stake in Stryker by 3.1% in the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 2,736 shares of the medical technology company's stock valued at $987,000 after acquiring an additional 83 shares during the period. Arete Wealth Advisors LLC increased its stake in shares of Stryker by 11.0% in the fourth quarter. Arete Wealth Advisors LLC now owns 1,204 shares of the medical technology company's stock worth $433,000 after purchasing an additional 119 shares in the last quarter. World Investment Advisors raised its position in shares of Stryker by 30.1% in the fourth quarter. World Investment Advisors now owns 10,593 shares of the medical technology company's stock valued at $3,814,000 after purchasing an additional 2,451 shares during the period. SevenBridge Financial Group LLC lifted its stake in shares of Stryker by 10.6% during the 4th quarter. SevenBridge Financial Group LLC now owns 1,496 shares of the medical technology company's stock valued at $584,000 after buying an additional 143 shares in the last quarter. Finally, OneAscent Financial Services LLC bought a new position in Stryker in the 4th quarter worth approximately $475,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Trading Up 0.5 %

Shares of Stryker stock traded up $1.63 during trading on Friday, reaching $350.02. The company's stock had a trading volume of 1,767,159 shares, compared to its average volume of 1,359,415. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The company has a market cap of $133.60 billion, a price-to-earnings ratio of 45.11, a PEG ratio of 2.93 and a beta of 0.93. The firm's 50-day moving average is $375.54 and its two-hundred day moving average is $373.63. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the company posted $3.46 EPS. On average, sell-side analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date is Monday, March 31st. Stryker's payout ratio is 43.30%.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Stifel Nicolaus increased their target price on Stryker from $400.00 to $440.00 and gave the stock a "buy" rating in a research report on Wednesday, January 29th. Wells Fargo & Company increased their price objective on Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a report on Wednesday, January 29th. JPMorgan Chase & Co. raised their target price on Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. Truist Financial upped their price target on Stryker from $409.00 to $413.00 and gave the company a "hold" rating in a research report on Thursday, January 30th. Finally, Royal Bank of Canada raised their price objective on shares of Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a research report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, Stryker presently has a consensus rating of "Moderate Buy" and a consensus target price of $423.05.

Insider Activity

In related news, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company's stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company's stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.